Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-05T16:05:40.830Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk Factors for and Impact of Infection or Colonization With Aztreonam-Resistant Pseudomonas aeruginosa

Published online by Cambridge University Press:  02 January 2015

Leanne B. Gasink ,
Neil O. Fishman ,
Irving Nachamkin ,
Warren B. Bilker  and
Ebbing Lautenbach
Leanne B. Gasink*
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
Neil O. Fishman
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia
Irving Nachamkin
Affiliation:
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
Warren B. Bilker
Affiliation:
Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
Ebbing Lautenbach
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
*
Hospital of the University of Pennsylvania, 3400 Spruce Street, 3 Silverstein Pavilion, Suite E, Philadelphia, PA 19104 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To identify risk factors for infection or colonization with aztreonam-resistant Pseudomonas aeruginosa and examine the impact of this organism on mortality.

Design.

A case-control study was performed to identify risk factors for infection or colonization with aztreonam-resistant P. aeruginosa. A cohort study was subsequently performed to examine the impact of aztreonam resistance on outcomes.

Setting.

A tertiary referral center in southeastern Pennsylvania.

Participants.

Inpatients with a clinical culture positive for P. aeruginosa between January 1, 1999, and December 31, 2000.

Results.

Of 720 P. aeruginosa, isolates, 183 (25.4%) were aztreonam-resistant and 537 (74.6%) were aztreonam susceptible. In a multivariable model, prior fluoroquinolone use (adjusted odds ratio [aOR], 1.81 [95% confidence interval {CI}, 1.17-2.80]), prior use of an antianaerobic agent (aOR, 1.56 [95% CI, 1.06-2.29]), and renal insufficiency (aOR, 1.59 [95% CI, 1.10-2.29]) were associated with infection or colonization with aztreonam-resistant P. aeruginosa, while older age (aOR, 0.98 [95% CI, 0.97-0.99] per year of age) was negatively associated with infection or colonization with this organism. In-hospital mortality was higher among subjects infected or colonized with aztreonam-resistant P. aeruginosa, compared with those who were infected or colonized with aztreonam-susceptible P. aeruginos (25.7% vs 16.8%;P = .009), but in multivariable analysis, no significant association was found between infection or colonization with aztreonam-resistant P. aeruginosa and mortality.

Conclusions.

Curbing the use of fluoroquinolones and antimicrobials with antianaerobic activity may be an effective strategy to limit the emergence of aztreonam-resistant P. aeruginosa.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 10 , October 2007 , pp. 1175 - 1180
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Fluit, AC, Jones, RN, Schmitz, FJ, Acar, J, Gupta, R, Verhoef, J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000;30:454–460.Google Scholar
2. Pfaller, MA, Jones, RN, Doern, GV, Kugler, K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762–1770.Google Scholar
3. Hilf, M, Yu, VL, Sharp, JA, Zuravleff, JJ, Korvick, JA, Muder, RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlation in a prospective study of 200 patients. Am J Med 1989;87:540–546.Google Scholar
4. Vidal, F, Mensa, J, Almela, M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Arch Intern Med 1996;156:2121–2126.Google Scholar
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control Dec 2003;31:481–498.Google Scholar
6. Obritsch, MD, Fish, DN, MacLaren, R, Jung, R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004;48:4606–4610.Google Scholar
7. Cao, B, Wang, H, Sun, H, Zhu, Y, Chen, M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004;57:112–118.Google Scholar
8. Paramythiotou, E, Lucet, JC, Timsit, JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670–677.Google Scholar
9. Ortega, B, Groeneveld, AB, Schultsz, C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004;25:825–831.Google Scholar
10. Troillet, N, Samore, MH, Carmeli, Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094–1098.Google Scholar
11. Harris, AD, Perencevich, E, Roghmann, MC, Morris, G, Kaye, KS, Johnson, JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002;46:854–858.Google Scholar
12. Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340–345.Google Scholar
13. Harris, AD, Karchmer, TB, Carmeli, Y, Samore, MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055–1061.Google Scholar
14. Barton, TD, Fishman, NO, Weiner, MG, Larosa, LA, Marr, A, Lautenbach, E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005;26:69–76.Google Scholar
15. Gasink, LB, Fishman, NO, Weiner, MG, Nachamkin, I, Bilker, WB, Lautenbach, E. Fluoroquinolone resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;119:526.e519–e526.e525.Google Scholar
16. Deyo, RA, Cherkin, DC, Ciol, MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.Google Scholar
17. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing: 11th Informational Supplement. Wayne, PA: NCCLS;2001:M100–S11.Google Scholar
18. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing: 10th Informational Supplement. Wayne, PA: NCCLS;2000:M100–S10.Google Scholar
19. Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold;1982.Google Scholar
20. Sun, J. A non-parametric test for interval censored failure time data with applications to AIDS studies. Stat Med 1996;15:1387–1395.Google Scholar
21. Andrade, SS, Jones, RN, Gales, AC, Sader, HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 2003;52:140–141.Google Scholar
22. Fluit, AC, Verhoef, J, Schmitz, FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. Eur J Clin Microbiol Infect Dis 2000;19:370–374.Google Scholar
23. Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among Pseudomonas aeruginosa: risk factors for emergence and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.Google Scholar
24. Gasink, LB, Fishman, NO, Weiner, MG, Nachamkin, I, Bilker, WB, Lautenbach, E. Epidemiology and impact of fluoroquinolone (FQ) resistant Pseudomonas aeruginosa (PA). In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 2006:343. Abstract K-1512.Google Scholar
25. Lee, SC, Fung, CP, Liu, PY, et al. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol 1999;20:205–207.Google Scholar
26. Flamm, RK, Weaver, MK, Thornsberry, C, Jones, ME, Karlowsky, JA, Sahm, DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004;48:2431–2436.Google Scholar
27. El Amari, EB, Chamot, E, Auckenthaler, R, Pechere, JC, Van Delden, C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859–1864.Google Scholar
28. Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640.Google Scholar
29. Gould, CV, Fishman, NO, Nachamkin, I, Lautenbach, E. Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infect Control Hosp Epidemiol 2004;25:138–145.Google Scholar
30. McCaig, LF, Besser, RE, Hughes, JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000 [published correction appears in Emerg Infect Dis 2003;9:609]. Emerg Infect Dis 2003;9:432–437.Google Scholar